Heart Health

Tim is at the heart of improving cardiovascular care

Professor Tim Palmer is pioneering the identification of new targeted drug therapies for the better management of cardiovascular disease, working alongside clinical colleagues in Cardiothoracic Surgery, Haematology, and Diabetes.

Localised inflammation of branch points within large blood vessels is a pivotal event in the development of atherosclerotic plaque responsible for heart attack and stroke. Inflammation is driven by long-term exposure to chemical signals termed "cytokines" which trigger multiple pathways that ultimately lead to the defective vascular cell function responsible for Cardiovascular Disease.

These processes are also responsible for the failure of bypass and stenting procedures used for acute treatment of patients who have suffered a heart attack.

Through his work, he is addressing a major health concern locally and globally.

 

Professor Tim Palmer

Professor Tim Palmer

Hull York Medical School Professor of Cardiovascular Biology

What benefits to people and society will your research bring, in the coming years?

Our team works closely with the NHS and industry aiming to develop new knowledge that will drive positive changes in the management of cardiovascular diseases and contribute to improving the lives of people locally and globally.

Professor Palmer heads the Hull York Medical School Centre for Biomedicine and Biomedical Institute for Multimorbidity and Chairs the UK Biochemical Society Research Area V (Signalling) panel.

He has secured over £6 million in research income from multiple funders (British Heart Foundation, BBSRC, Diabetes UK, Wellcome Trust) and has successfully trained 18 PhD students.

Who are the key collaborators/networks/stakeholders you currently work with?

Locally, I collaborate with Professor Mahmoud Loubani (Cardiothoracic Surgery, Castle Hill Hospital) on how diabetes increases risk of vein graft failure in bypass surgery, and Dr David Allsup (HYMS, Queen’s Oncology Centre, Castle Hill Hospital) on targeted re-purposing anti-diabetes drugs to manage bleeding defects in patents with specific blood cancers.

More widely, I collaborate with research groups in Glasgow, Edinburgh, Leeds, York, Sheffield and Bradford as well as Europe and Australia.

Can you tell us about any other current research?

Working with clinical colleagues at Castle Hill Hospital and Hull Royal Infirmary, we are also examining the mechanisms responsible for the increased  cardiovascular risk in diabetes patients. By understanding these processes, we aim to identify targets for developing more effective treatments specifically for diabetes patients.

What drives your passion for research?

I am fortunate to have been successful enough to pursue research questions I am passionate about, and work and travel around the world to progress them. 

What do you like most about working at the University of Hull?

I am lucky to work with many talented, supportive and hard-working colleagues.

Community Impact

Publications: 

Top